Sage Journals: Discover world-class research

Abstract

French

Objective

To assess the association between receipt of minimally adequate treatment (MAT) and mortality in a sample of community primary care older adults with depression and anxiety.

Method

The present study was conducted among a sample of 358 older adults ( ≥ 65 years old) with depression or an anxiety disorder recruited in primary care practices between 2011 and 2013. Participants agreed to link their health survey and administrative data for the 3 years preceding and following the baseline interview. Depression and anxiety disorders were based on self-reported symptoms aligned with DSM-5 criteria and physician diagnoses (International Classification of Diseases [ICD], 9^th and 10^th revisions). MAT was defined according to Canadian guidelines and include receipt of pharmacotherapy and ≥ 4 medical visits within 3 months or a number of psychotherapy sessions (individual, group, or family) over 12 months (depression: ≥8; anxiety disorders: ≥5 to 7). All-cause 3-year mortality was ascertained from the vital statistics death registry in Québec. Propensity score weighted regression analysis was conducted to assess the association between receipt of MAT and mortality adjusting for individual, clinical, and health system study factors.

Results

Receipt of MAT was associated with a reduced risk of mortality (hazard ratio [HR]: 0.27; 95% confidence interval [95% CI], 0.12 to 0.62). Individual and clinical factors associated with increased mortality included older age, male sex, being single, low functional status, and increased physical disorders and cognitive functioning. Lifestyle factors associated with reduced and increased mortality included alcohol consumption and smoking, respectively. Health system factors such as perceived adequate number of visits to speak to the doctor about emotional problems and continuity of care were associated with reduced mortality.

Conclusion

The current study highlights the important role of primary care physicians in detecting and providing MAT for older adults with depression and anxiety, as this may have an effect on longevity.

Keywords

mortality minimally adequate care depression anxiety disorders primary care older adults

Introduction

In Canada, the highest increase in the prevalence of mental disorders in the next 20 years will be in older adults with estimates for anxiety and depression reaching 19% in females and 10% in males¹. Past year prevalence estimates in older adults are 3% and 20% for major and dimensional depression assessed through standardized and self-reported questionnaires², and between 6% and 17% for anxiety disorders^3–5. With individuals living longer, a Canadian study, reporting on the distribution of chronic conditions at the time of death, showed a 29% increase in the presence of mood disorders over a 10-year period⁶.

In large international population registry studies, the presence of mental disorders has been associated with excess mortality and premature death due to suicide and chronic medical conditions^7–10. Research in Canada analyzing data from the Quebec Integrated Chronic Disease Surveillance System showed that the presence of a mental disorder was associated with an 8 and 5-year reduced life expectancy due to suicide and physical comorbidities in men and women¹¹. When looking at differences in life expectancy by disorders, reductions were observed in both men and women for schizophrenia¹¹ and personality disorders¹². Reduced life expectancy was also seen in men with mood or anxiety disorders but not in women¹¹. A possible explanation put forth by authors was that women are more likely than men to consult for mental health reasons and may therefore be more likely to be detected and treated for their mental health and chronic conditions¹¹.

In a general population survey in the United States, the presence of self-reported anxiety or depression was not associated with mortality in those who had consulted a mental health professional, but was associated with increased mortality in those who had not consulted¹⁰. In older adult Veterans, quality of care defined as an adequate supply of antidepressants and follow-up to monitor drug use was associated with a decreased risk of mortality¹³. The majority of older adults however either receive no or inadequate antidepressant treatment and follow-up mental health care^14–16.

In Canada, general population studies have shown that only up to 42% of older adults with a mood or anxiety disorder consulted for their mental health in the past year^17,18. When they do, close to 80% of older adults consult their family physician or general practitioner¹⁷. The current primary care study can contribute to the literature regarding the association between receipt of minimally adequate treatment (MAT) and mortality in older adults with anxiety and depression. The study includes linked health survey and medico-administrative data minimizing information bias regarding the presence of a mental disorder and treatment and allow adjusting for sociodemographic, clinical, and psychosocial variables as potential confounders. This overcomes some of the limitations of previous registry studies in Canada using medico-administrative data only, which would only capture those seeking health services.

Methods

Study Sample

This study is based on a convenience sample of 1811 older adults participating in the Études sur la santé des ainés (ESA) Services study and recruited in primary care practice waiting rooms in one of the largest health regions in the province of Quebec between 2011 and 2013. Study details have been presented elsewhere¹⁹. Interested participants were contacted by the study coordinator describing study objectives and were interviewed at home by trained health professionals using a computer assisted questionnaire. Cognitive functioning was assessed with a French translation of the Mini-Mental State Examination (MMSE) adapted for at-home interviews in community-living older adults^20,21. Individuals scoring less than 22 were not included in this study. Respondents gave written consent to link their data to health administrative data from the Régie de l’Assurance Maladie du Québec (RAMQ), the Maintenance et exploitation des données pour l'étude de la clientèle hospitalière (MED-ECHO) dataset, and the vital statistics death registry in the 3 years preceding and following the baseline interview. These administrative databases provide data on outpatient and emergency department (ED) visits, hospitalizations, physician diagnoses, medications delivered under the Quebec drug plan, and date and cause of death. Permission to link data was obtained from the Commission d’Accès à l’Information du Québec and the compilation was based on data from the © Government of Quebec. Ethics approval for the ESA Services longitudinal study is obtained annually from the ethics committee of the CISSS – Montérégie Centre and CIUSSS Estrie – Centre Hospitalier Universitaire de Sherbrooke.

Of the 1811 participants, 1456 gave access to their administrative data and were covered under Quebec's public drug plan. Of these, 358 had either a physician diagnosis of depression or an anxiety disorder or self-reported symptoms in the last 6 months consistent with those used for DSM-5 criteria (with the exception of functioning impairment) for major depression, social phobia, specific phobia, generalized anxiety disorder, panic disorder, and agoraphobia²². The ESA mental health modules of the standardized questionnaire have been described in detail elsewhere²³. As an example, individuals were identified as having major depression if they reported five of the nine symptoms of depression every day for at least two consecutive weeks, including the presence of depressed mood or loss of interest, and that these symptoms were not due to another disease or a medication²². The presence of a physician diagnosis of depression and an anxiety disorder in the health administrative databases was assessed during the 6 months preceding and following the baseline interview. The following codes from the 9th and 10^th revisions of the International Classification for Diseases (ICD) were used: 300.0; 300.2; 311.0; 311.9; 300.4; F32; F33; F34.1; F40; and F41^24–28. Individuals having other mental disorders weren’t excluded from the analytic sample.

Measures

All-cause 3-year mortality post-interview was ascertained from the vital statistics death registry in the province of Québec²⁹.

MAT for depression and anxiety disorders was defined using minimal quality of care indicators based on Canadian clinical guidelines and relevant literature^30–37^. MAT for depression was based on the presence of a first, second, or third line recommended antidepressant prescription and at least four follow-up visits with a primary care provider (PCP) within 3 months of the diagnosis or prescription delivered or eight sessions of psychotherapy (individual, group, or family) within a year^31,35,37,38. MAT for anxiety disorders (except for specific phobia) was based on the presence of a first, second, or third line recommended medication delivered including an antidepressant, anxiolytic, or other recommended medication and at least four follow-up visits with a PCP within 3 months of the diagnosis or prescription delivered or seven sessions of psychotherapy (individual, group, or family) within a year^30,34,36. Other guideline-recommended medications include anticonvulsants, atypical antipsychotics (quetiapine, risperidone), buspirone, and atomoxetine³⁰. Since pharmacological treatment is not recommended for specific phobia, MAT was defined as the presence of five psychotherapy sessions within a year. The detailed description of MAT for depression and anxiety disorders has previously been described elsewhere³⁹.

Although the recommendations for the use of anxiolytic drugs in older adults have evolved in the last decade where some long-acting benzodiazepines may be appropriate for only certain conditions such as severe generalized anxiety disorders, the Beer's criteria state that the use of benzodiazepines in older adults should be avoided^40,41. Additional sensitivity analyses were carried out where the presence of a benzodiazepine was not considered in the definition of minimal adequate treatment for anxiety disorders.

The following individual factors measured at baseline were considered as potential confounders in the multivariable models: age; sex (male/female); education (years); marital status (with vs. without partner); total household revenues before taxes (≤25,000$ vs. ˃ 25,000$, to closely reflect low income cut-offs)⁴², functional status (high functioning [first–third quartiles] vs. low functioning [fourth quartile]) was based on 8 dimensions of Instrumental Activities of Daily Living (IADL)^43,44; number of physical diseases was based on a list of 17 medical chronic conditions (related to, e.g., cancer, headaches/migraines, arthropathy, musculoskeletal disorders, respiratory disease, cardiovascular disease, gastrointestinal disease, liver disease, urinary tract problems, thyroid problems, diabetes, dermatologic conditions); cognitive functioning was measured with the ESA French translation of the MMSE with possible scores ranging from 22 to 30^20,21; childhood trauma (presence vs. absence)⁴⁵; satisfaction with life was assessed with a French adapted version of the Satisfaction with Life Scale (5–25)^46,47; current smoker (yes vs. no), alcohol consumption in the past 6 months (yes vs. no); and number of sessions per week exercised at least 20 min. Patient perceptions about mental health treatment were assessed with the following three questions: (1) perceived physician availability to speak of emotional problems, (2) perceived adequate number of visits with the doctor to speak about emotional problems, and (3) perceived effectiveness of health professionals helping resolve emotional problems. The five answer choices for each question were: certainly, a lot, moderately, a little, not at all, and don’t know. Answers to the three variables were dichotomized and analyzed as follows: Certainly/a lot/moderately versus a little/not at all/don’t know.

Health system factors were also considered and included the number of outpatient and ED visits and hospitalizations in the 3 years preceding the baseline interview, the median distance to private clinics for general medical services, and the median distance to hospital for general medical and psychiatric services. Continuity of care in the 3 years post-interview was the ratio between the number of different physicians consulted over the total number of visits in ambulatory care⁴⁸, which has been previously used in populations of older adults with chronic diseases^49,50. A possible score is between 0 and 1, with higher scores representing higher continuity of care⁵¹. Outpatient and ED visits, hospitalizations and inpatient stay, and the continuity of care index were ascertained using the RAMQ and MED-ECHO administrative database. The median distance to private clinics and hospital was estimated using the Consommation et offre normalisée des services offerts par les Médecins (CONSOM) provincial database⁵².

Analyses

Differences in proportions and means for categorical and continuous variables were ascertained using chi-square and Student’s t-test statistics. Bivariate and multivariable time to event analyses were carried out to assess receipt of MAT and the risk of death controlling for individual and health system factors.

To address the potential treatment selection bias in this observational study, propensity score analysis was carried out where the inverse probability of receipt of MAT was calculated^53,54. A propensity score weighted regression model was fitted to assess the effect of receipt of MAT on the risk of death adjusting for study variables. In the analysis of the propensity score, variables that were associated with the outcome of interest, mortality, and factors assessed before treatment assignment were included in the logistic regression predicting receipt of MAT⁵⁵. In the present study, the variables used to assess the probability of receiving MAT were age, sex, marital status, functional disability, number of physical conditions, smoking status, exercise, and number of hospitalizations and ED visits in the past 3 years. Additional analyses also considered the effect of receipt of MAT excluding benzodiazepine use from the definition. Hazard ratios (HRs) are reported with their 95% confidence intervals (95% CIs). All hypotheses were tested at a 95% significance level. Statistical analyses were performed using SAS version V.9.4.

Results

In the present primary care sample of older adults, 77% (n = 274) had an anxiety disorder, 13% (n = 46) depression, and 10% (n = 38) had both. The 3-year risk of mortality reached 6.7% (n = 24). Thirty-nine percent of participants received MAT for their depression or anxiety disorder. The characteristics of the sample are shown in Table 1. In the bivariate analyses, age, marital status, physical functioning, lifestyle behaviors including alcohol consumption and smoking, past hospitalizations and ED visits, and continuity of care were associated with mortality.

Table 1.

Characteristics of Study Sample in Relation to 3-Year Mortality.

	Mortality n (%)		Hazard ratio (HR) (95% CI)
	Yesn = 24 (6.7%)	Non = 334 (93.3%)	Hazard ratio (HR) (95% CI)
Receipt of minimally adequate treatment (MAT) Yes No	6 (25.0%) 18 (75.0%)	133 (39.8%) 201 (60.2%)	0.52 (0.20 to 1.30)
Individual factors
Age, years (Mean ± SD)	78.3 ± 6.7	72.6 ± 5.5	1.15 (1.08 to 1.22)
SexMaleFemale	10 (41.7%) 14 (58.3%)	101 (30.2%)233 (69.8%)	-0.62 (0.28 to 1.39)
Education, years (Mean ± SD)	10.7 ± 3.5	10.4 ± 4.0	1.02 (0.92 to 1.12)
Marital statusWithout partnerWith partner	16 (66.7%)8 (33.3%)	143 (42.8%)191 (57.2%)	2.59 (1.11 to 6.06)-
Income>25,000$≤25,000$	12 (50.0%)12 (50.0%)	191 (57.2%) 143 (42.8%)	0.76 (0.34 to 1.69)-
Functional status, worst quartileFourth quartileFirst–third quartiles	15 (62.5%)9 (37.5%)	75 (22.6%)257 (77.4%)	5.27 (2.30 to 12.03)-
Number of physical disorders (Mean ± SD)	7.0 ± 2.7	6.0 ± 2.5	1.16 (0.99 to 1.37)
Cognitive functioning (MMSE scores, Mean ± SD)	28.0 ± 1.8	28.1 ± 1.8	0.95 (0.77 to 1.18)
Childhood traumaPresenceAbsence	6 (25.0%)18 (75.0%)	79 (23.7%)255 (76.4%)	1.07 (0.43 to 2.70)-
Satisfaction with life (Mean ± SD)	19.7 ± 4.2	19.9 ± 4.5	0.99 (0.91 to 1.08)
Alcohol consumption in past 6 monthsYesNo	11 (45.8%)13 (54.2%)	237 (71.0%)97 (29.0%)	0.36 (0.16 to 0.81)-
Current smokingYesNo	7 (29.2%)17 (70.8%)	27 (8.1%)307 (91.9%)	4.10 (1.70 to 9.88)-
Number of sessions per week exercising at least 20 min (Mean ± SD)	1.9 ± 2.4	3.2 ± 3.5	0.86 (0.73 to 1.01)
Patient perceptions relating to mental health care
Physician availability to speak of emotional problemsCertainly/a lot/moderatelyA little/not at all/don’t knowMissing	17 (70.8%)7 (29.2%)0 (0%)	261 (78.9%)70 (21.1%)3 (100%)	0.67 (0.28 to 1.60)-
Adequate number of visits with the doctor to speak about emotional problemsCertainly/a lot/moderatelyA little/not at all/don’t knowMissing	13 (54.2%)11 (45.8%)0 (0%)	235 (71.0%)96 (29.0%)3 (100%)	0.49 (0.22 to 1.10)-
Effectiveness of health professional in helping resolve emotional problemsCertainly/a lot/moderatelyA little/not at all/don’t knowMissing	19 (79.2%)5 (20.8%)0 (0%)	262 (78.7%)71 (21.3%)1 (100%)	1.03 (0.38 to 2.75)-
Health system factors	(Mean ± SD)
Number of outpatient visits, past 3 years	31.5 ± 18.4	28.1 ± 20.3	1.01 (0.99 to 1.03)
Number of hospitalizations, past 3 years	5.1 ± 5.1	2.1 ± 2.6	1.17 (1.10 to 1.25)
Number of ED visits, past 3 years	6.7 ± 5.8	4.0 ± 5.2	1.06 (1.01 to 1.11)
Continuity of care in the 3 years follow-up	0.16 ± 0.13	0.30 ± 0.23	0.01 (0.001 to 0.33)
Median distance to private clinics for general medical services	3.9 ± 2.3	3.8 ± 2.7	1.01 (0.88 to 1.17)
Median distance to hospital for general medical services	8.5 ± 6.3	8.5 ± 6.9	1.00 (0.94 to 1.06)
Median distance to hospital for psychiatric services	13.6 ± 14.9	14.5 ± 16.0	1.00 (0.97 to 1.02)

Note: CI: confidence interval; ED: emergency department, MMSE: Mini-Mental State Examination; SD: standard deviation

The weighted and unweighted multivariable analyses are shown in Table 2. Both the unweighted (HR 0.27; 95% CI, 0.08 to 0.93) and weighted (HR 0.27; 95% CI, 0.12 to 0.62) analyses showed a significant association between receipt of MAT and mortality. Additional sensitivity analyses where benzodiazepine use was not considered in the definition of MAT showed similar results.

Table 2.

Multivariable Analyses of Mortality as a Function of Minimally Adequate Treatment (MAT) and Study Variables (n = 351).

	Hazard ratio (HR) (95% CI)	*HR (95% CI)
Receipt of MAT	0.27 (0.08 to 0.93)	0.27 (0.12 to 0.62)
Individual factors
Age (years)	1.22 (1.09 to 1.37)	1.20 (1.11 to 1.29)
Sex (female vs. male)	0.33 (0.09 to 1.17)	0.33 (0.14 to 0.76)
Education (years)	1.10 (0.94 to 1.28)	1.07 (0.97 to 1.18)
Marital status (without partner vs. with partner)	3.11 (0.75 to 12.90)	3.97 (1.56 to 10.10)
Income (higher vs. lower)	1.89 (0.51 to 6.99)	2.14 (0.89 to 5.14)
Functional status (worst quartile)	4.92 (1.53 to 15.89)	5.99 (2.74 to 13.08)
Number of physical disorders	1.43 (1.06 to 1.94)	1.51 (1.23 to 1.84)
Cognitive functioning	1.38 (0.99 to 1.90)	1.32 (1.07 to 1.63)
Childhood trauma	1.28 (0.35 to 4.73)	1.36 (0.57 to 3.22)
Satisfaction with life	0.97 (0.86 to 1.09)	0.97 (0.89 to 1.05)
Alcohol consumption in the past 6 months	0.38 (0.13 to 1.14)	0.32 (0.15 to 0.67)
Current smoking	8.70 (2.07 to 36.51)	7.84 (3.04 to 20.24)
Number of sessions per week exercising at least 20 min	0.88 (0.72 to 1.07)	0.89 (0.78 to 1.01)
Patient perceptions relating to mental health care^a
Physician availability to speak of emotional problems	0.53 (0.13 to 2.21)	0.52 (0.20 to 1.33)
Adequate number of visits with the doctor to speak about emotional problems	0.45 (0.40 to 1.43)	0.41 (0.19 to 0.91)
Effectiveness of health professionals in helping resolve emotional problems	1.33 (0.38 to 4.62)	1.53 (0.66 to 3.59)
Health system factors
Number of outpatient visits, past 3 years	0.99 (0.95 to 1.03)	0.98 (0.95 to 1.01)
Number of hospitalizations, past 3 years	1.34 (1.11 to 1.62)	1.36 (1.19 to 1.55)
Number of ED visits, past 3 years	0.86 (0.72 to 1.03)	0.87 (0.77 to 0.99)
Continuity of care in the 3 years follow-up	0.003 (0.001 to 0.69)	0.004 (0.001 to 0.12)
Median distance to private clinics for general medical services	1.09 (0.80 to 1.48)	1.09 (0.89 to 1.33)
Median distance to hospital for general medical services	1.04 (0.94 to 1.16)	1.04 (0.97 to 1.12)
Median distance to hospital for psychiatric services	1.01 (0.97 to 1.05)	1.00 (0.97 to 1.03)

Note: ^aPatient perceptions relating to mental health care included the comparison between the following categories: Certainly/a lot/moderately versus a little/not at all/don’t know. *Propensity score inverse probability weighting.CI: confidence interval; ED: emergency department.

Individual and health system factors that were significantly associated with increased mortality in the weighted analyses included older age (HR: 1.20; 95% CI, 1.11 to 1.29), being single (HR: 3.97; 95% CI, 1.56 to 10.10), reduced functional status (worst quartile) (HR: 5.99; 95% CI, 2.74 to 13.08), increased number of physical disorders (HR: 1.51; 95% CI, 1.23 to 1.84), higher cognitive functioning (HR: 1.32; 95% CI, 1.07 to 1.63), current smoking (HR: 7.84; 95% CI, 3.04 to 20.24), and past hospitalizations (HR: 1.36; 95% CI, 1.19 to 1.55). Factors that were associated with reduced mortality included female sex (HR: 0.33; 95% CI, 0.14 to 0.76), alcohol consumption (HR: 0.32; 95% CI 0.15 to 0.67), patient perception of having had an adequate number of visits to speak to the doctor about emotional problems (HR: 0.41; 95% CI, 0.19 to 0.91) and increased continuity of care (HR: 0.004; 95% CI, 0.001 to 0.012).

Discussion

In the present primary care sample of older adults with self-reported and physician-diagnosed anxiety or depression, receipt of MAT was associated with reduced mortality. Additional analyses where the presence of a benzodiazepine prescription was excluded from the definition of receipt of MAT showed similar results.

Improved mental health follow-up of older adults with major depression and reduced mortality was similarly reported in the PROSPECT study⁵⁶. The trial followed for 5 years older adults in primary care settings that were randomized to practices receiving either primary care physician education sessions alone or adding education for patient families, and a depression care manager within practice⁵⁷. In a large U.S. Veteran population, adequate mental health care, defined as at least three visits within a 3-month period after diagnosis^58,59, was associated with a reduced risk of 1-year mortality. Also in a sample of Veterans, an adequate supply of antidepressants measured on the basis of the medication possession ratio (≥80%)¹³ was not associated with mortality. Although these study populations are not directly comparable, the findings mostly support the importance of quality mental health care and continuity of primary care for older adults with depression and anxiety in reducing mortality. Future studies should focus on assessing which component of quality mental health care is associated with a decreased risk of mortality.

A previous study in older adults showed that the presence of major depression, anxiety, suicidal ideation, and psychological distress was associated with low satisfaction with continuity of care, patient–provider interactions, and low satisfaction with adequacy of care. While controlling for a number of individual socioeconomic, clinical, and lifestyle factors, it was interesting to note, that patient perceptions relating to physician availability to speak of emotional problems and perceived effectiveness of consulting health professional in resolving emotional problems was not associated with mortality. Increased continuity of care and patient-perceived adequate number of visits to speak about emotional problems in the present study were associated with a reduced risk of mortality, which has been reported elsewhere^60–62.

The present study included a number of strengths and limitations. First, the presence of mental disorders was based on information from self-reports and physician diagnoses, which may have reduced the potential for information bias related to social desirability in health surveys and underreporting of diagnoses in health administrative data as physicians are not obligated to report for payment⁶³. Second, the definition of MAT included receipt of individual, group, or family psychotherapy either in the public or private sector adding to the validity of the measure overall. Follow-up visits with psychiatrists weren’t considered in the definition. However, only four participants had a psychiatrist visit in the 12 months following the interview and no participant had more than two visits, therefore minimizing any misclassification bias. Although treatment recommendations for different anxiety disorders differ, the same definition of minimal adequate treatment was applied for all anxiety disorders included in the study with the exception of specific phobia. Third, to reduce the potential selection bias related to receipt of MAT, propensity score analysis was carried out while including the control of a number of individual and health system factors. Although the majority of variables were assessed by self-report and may have been subject to recall and social desirability bias, we do not expect the potential information bias to have been different between deceased and non-deceased individuals. Fourth, in the absence of a randomized controlled trial, confounding by indication can’t be ruled out and the results can’t be considered as proving that MAT for depression or anxiety decreases all-cause mortality and this despite the use of a propensity score analysis. Fifth, given that this was a convenience sample of French speaking older adults consulting in primary care practices, a possible selection bias remains. However, the majority of older adults in the province of Quebec has a family physician⁶⁴ and consult their primary care physicians annually. Sixth, recruitment of participants was limited to one specific health administrative region in the province of Quebec, which may have limited generalizability. However, the region was one of the largest in the province with the highest proportion of older adults and covered geographically rural and urban regions. Seventh, using an MMSE cut-off of 22, the study sample included individuals with mild impairment but excluded individuals with substantial deficits in cognitive functioning⁶⁵, therefore limiting the generalizability of conclusions to individuals with more severe clinical profiles. Although not observed in the multivariable analyses, the propensity score analysis unexpectedly showed an increase in mortality with higher cognition. This finding is unexpected as cognitive impairment has previously been associated with increased mortality. It is possible that this is a chance finding given the small sample size or may reflect residual confounding. We note that this sample generally had good cognitive functioning with a mean MMSE score of 28 and in some analyses decline in cognition, rather than baseline cognition, has been more robustly associated with mortality when baseline comorbidities have been adjusted for⁶⁶. Lastly, the sample size of this study with respect to cases of depression and deaths was limited and may have led to increased uncertainty surrounding some estimates.

Although significant associations were observed with the main independent variable of interest and mortality, future larger and longer longitudinal studies are needed to better ascertain the effect of quality health care on mortality for individuals with depression and anxiety. For instance, it was not possible to assess whether the associations observed were mainly explained by pharmacotherapy and follow-up, psychotherapy or both. Given that the combined effect of pharmacotherapy and psychotherapy has been associated with more favorable outcomes and longer remission⁶⁷, it may be of interest to assess their specific and combined effect on mortality. Further, given the important costs and negative health outcomes associated with the use of benzodiazepines in older adults, alternative treatments such as cognitive-behavioral therapy may be more appropriate in treating anxiety disorders and other related problems⁶⁸.

In summary, the present study underlines the importance of primary care physicians in detecting and providing adequate quality mental health care for older adults with depression and anxiety, as this may be associated with longevity.

Footnotes

Acknowledgment

The authors acknowledge D. Berbiche for merging dataset and the preparation of study variables.

Authors’ Contribution

HMV defined the analytic plan and performed all statistical analyses and wrote the first draft of the paper. CLL contributed to the analytic plan. CLL, SG, and PR contributed to the interpretation of results and revised the manuscript. All authors read and approved the final manuscript.

Data Availability

The authors are not legally authorized to share or publicly publish linked survey and health administrative data due to privacy or ethical restrictions related to the use of administrative provincial health data. Participants were not requested to give informed consent for data sharing. Questions should be addressed to the research ethics committee. The province of Québec’s “Commission d’Accès à l’Information” gave approval to merge these datasets.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The longitudinal ESA Services study was supported by an operating grant from the Fonds de Recherche en santé du Québec (FRSQ) (#16000, #22251, PI: Dr. M Préville). The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript. C. Lamoureux-Lamarche was the recipient of a PhD’s bursary from the Fonds de Recherche du Québec – Santé (FRQS) in partnership with the SPOR Quebec SUPPORT Unit. S Grenier was supported by a Junior 2 salary award from the FRQS during the study.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the FRSQ en Santé Québec, (grant numbers #16000 and #22251).

ORCID iDs

Helen-Maria Vasiliadis

Catherine Lamoureux-Lamarche

References

Smetanin

Stiff

Briante

, et al. The life and economic impact of major mental illnesses in Canada: 2011 to 2041. Toronto, Ontario: Mental Health Commission of Canada; 2011.

Volkert

Schulz

Harter

, et al. The prevalence of mental disorders in older people in western countries - a meta-analysis. Ageing Res Rev. 2013;12(1):339–353.

Andreas

Schulz

Volkert

, et al. Prevalence of mental disorders in elderly people: the European MentDis_ICF65 + study. Br J Psychiatry. 2017;210(2):125–131.

Schuurmans

van Balkom

. Late-life anxiety disorders: a review. Curr Psychiatry Rep. 2011;13(4):267–273.

Andreescu

Varon

. New research on anxiety disorders in the elderly and an update on evidence-based treatments. Curr Psychiatry Rep. 2015;17(7):53.

Rosella

Kornas

Huang

, et al. Accumulation of chronic conditions at the time of death increased in ontario from 1994 To 2013. Health Aff (Millwood). 2018;37(3):464–472.

Erlangsen

Andersen

Toender

, et al. Cause-specific life-years lost in people with mental disorders: a nationwide, register-based cohort study. Lancet Psychiatry. 2017;4(12):937–945.

Berardi

Stivanello

Chierzi

, et al. Mortality in mental health patients of the Emilia-romagna region of Italy: a registry-based study. Psychiatry Res. 2021;296:113702.

Baxter

Page

Whiteford

. Factors influencing risk of premature mortality in community cases of depression: a meta-analytic review. Epidemiol Res Int. 2011;2011:832945.

10.

Plana-Ripoll

Pedersen

Agerbo

, et al. A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. The Lancet. 2019;394(10211):1827–1835.

11.

Lesage

Rochette

Émond

, et al. A surveillance system to monitor excess mortality of people with mental illness in Canada. CPA. 2015;60(12):571–579.

12.

Cailhol

Pelletier

Rochette

, et al. Prevalence, mortality, and health care use among patients with cluster B personality disorders clinically diagnosed in quebec: a provincial cohort study, 2001–2012. Can J Psychiatry. 2017;62(5):336–342.

13.

Cully

Zimmer

Khan

, et al. Quality of depression care and its impact on health service use and mortality among veterans. Psychiatr Serv. 2008;59(12):1399–1405.

14.

Wang

Schneeweiss

Brookhart

, et al. Suboptimal antidepressant use in the elderly. J Clin Psychopharmacol. 2005;25(2):118–126.

15.

Barry

Abou

Simen

, et al. Under-treatment of depression in older persons. J Affect Disord. 2012;136(3):789–796.

16.

Kok

Reynolds

, 3rd. Management of depression in older adults: a review. JAMA. 2017;317(20):2114–2122.

17.

Preville

Vasiliadis

Boyer

, et al. Use of health services for psychological distress symptoms among community-dwelling older adults. Can J Aging. 2009;28(1):51–61.

18.

Mosier

Vasiliadis

Lepnurm

, et al. Prevalence of mental disorders and service utilization in seniors: results from the Canadian community health survey cycle 1.2. Int J Geriatr Psychiatry. 2010;25(10):960–967.

19.

Préville

Mechakra-Tahiri

Vasiliadis

H-M

, et al. Family violence among older adult patients consulting in primary care clinics: results from the ESA (enquête sur la santé des aînés) services study on mental health and aging. CPA. 2014;59(8):426–433.

20.

Folstein

McHugh

. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198.

21.

Hudon

Potvin

Turcotte

M-C

, et al. Normalisation du Mini-mental state examination (MMSE) chez les québécois francophones âgés de 65 ans et plus et résidant dans la communauté. Can J Aging. 2009;28(4):347–357.

22.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). Washington, DC: American Psychiatric Pub. 2013.

23.

Preville

Boyer

Grenier

, et al. The epidemiology of psychiatric disorders in quebec's older adult population. Can J Psychiatry. 2008;53(12):822–832.

24.

Blais

Partlová

Lachaine

, et al.

La conformité aux guides de traitement de la dépression est-elle associée à une réduction des coûts des services de santé?

Pratiques et Organisation des Soins. 2010;41(4):349–357.

25.

Sewitch

Blais

Rahme

, et al. Pharmacologic response to a diagnosis of late-life depression: a population study in quebec. CPA. 2006;51(6):363–370.

26.

Alaghehbandan

MacDonald

Barrett

, et al. Using administrative databases in the surveillance of depressive disorders—case definitions. Popul Health Manag. 2012;15(6):372–380.

27.

Régie de l’Assurance Maladie du Québec . Répertoire des diagnostics - CIM-10. https://www.ramq.gouv.qc.ca/fr/professionnels/medecins-specialistes/facturation/repertoire-diagnostics/Pages/cim-10_par-code.aspx. Accessed 23 April, 2020.

28.

Régie de l’Assurance Maladie du Québec . Répertoire des diagnostics - CIM-9. https://www.ramq.gouv.qc.ca/fr/professionnels/medecins-specialistes/facturation/repertoire-diagnostics/Pages/cim-9_par-code.aspx. Accessed 23 April, 2020.

29.

Blais

Jean

Sirois

, et al. Quebec integrated chronic disease surveillance system (QICDSS), an innovative approach. Chronic Dis Inj Can. 2014;34(4):226–235.

30.

Katzman

Bleau

Blier

, et al. Canadian Clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(1):S1.

31.

MacQueen

Frey

Ismail

, et al. Canadian Network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations: youth, women, and the elderly. CPA. 2016;61(9):588–603.

32.

Parikh

Quilty

Ravitz

, et al. Canadian Network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 2. Psychological treatments. CPA. 2016;61(9):524–539.

33.

Wolitzky-Taylor

Horowitz

Powers

, et al. Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev. 2008;28(6):1021–1037.

34.

Roberge

Fournier

Duhoux

, et al. Mental health service use and treatment adequacy for anxiety disorders in Canada. Soc Psychiatry Psychiatr Epidemiol. 2011;46(4):321–330.

35.

Turgeon

Guénette

. Portrait de l'usage des antidépresseurs chez les adultes assurés par le régime public d'assurance médicaments du québec: rapport final. Québec, Québec: Conseil du médicament. 2011.

36.

Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Canadian journal of psychiatry Revue canadienne de psychiatrie. 2006;51(8 Suppl 2):9S.

37.

Canadian Coalition for Senior’s Mental Health. National Guidelines for Seniors’ Mental Health. The Assessment and Treatment of Depression . 2006.

38.

Kennedy

Lam

McIntyre

, et al. Canadian Network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. CPA. 2016;61(9):540–560.

39.

Lamoureux-Lamarche

Berbiche

Vasiliadis

. Treatment adequacy and remission of depression and anxiety disorders and quality of life in primary care older adults. Health Qual Life Outcomes. 2021;12(1):218.

40.

The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–631.

41.

The American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–2246.

42.

Statistics Canada. Table 11-10-0241-01: Low income cut-offs (LICOs) before and after tax by community size and family size, in current dollars. Statistics Canada;2021.

43.

Gontijo Guerra

Berbiche

Vasiliadis

. Changes in instrumental activities of daily living functioning associated with concurrent common mental disorders and physical multimorbidity in older adults. Disabil Rehabil. 2021;43(25):3663–3671.

44.

Hébert

Guilbault

Desrosiers

, et al. The functional autonomy measurement system (SMAF): A clinical based instrument for measuring disabilities and handicaps in older people. J Can Geriatr Soc. 2001:1–7.

45.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.

46.

Blais

Vallerand

Pelletier

, et al. L'échelle de satisfaction de vie: validation canadienne-française du" satisfaction with life scale.". CJBS. 1989;21(2):210.

47.

Diener

Emmons

Larsen

, et al. The satisfaction with life scale. J Pers Assess. 1985;49(1):71–75.

48.

Bice

Boxerman

. A quantitative measure of continuity of care. Med Care. 1977;15(4):347–349.

49.

Pollack

Hussey

Rudin

, et al. Measuring care continuity: a comparison of claims-based methods. Med Care. 2016;54(5):e30–e34.

50.

White

. Continuity of care in older adults with multiple chronic conditions. University of Washington; 2016. https://digital.lib.washington.edu/researchworks/bitstream/handle/1773/37142/White_washington_0250E_16491.pdf?sequence=1&isAllowed=y

51.

Hussey

Schneider

Rudin

, et al. Continuity and the costs of care for chronic disease. JAMA Intern Med. 2014;174(5):742–748.

52.

Ministère de la Santé et des Services Sociaux (MSSS). Sources de données et métadonnées - CONSOM. https://www.msss.gouv.qc.ca/professionnels/documentation-sources-de-donnees-et-indicateurs/sources-de-donnees-et-metadonnees/consom/. Published 2016. Accessed 22 March, 2020.

53.

Rosenbaum

Rubin

. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.

54.

D'Agostino

Jr . Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265–2281.

55.

Leslie

Ghomrawi

. The Use of Propensity Scores and Instrumental Variable Methods to Adjust For Treatment Selection Bias SAS Global Forum 2008 - Statistics and Data Analysis 2008;Paper 366–2008.

56.

Gallo

Bogner

Morales

, et al. The effect of a primary care practice-based depression intervention on mortality in older adults: a randomized trial. Ann Intern Med. 2007;146(10):689–698.

57.

Bruce

Ten Have

Reynolds

, 3rd, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. JAMA. 2004;291(9):1081–1091.

58.

Jones

Turvey

Carney-Doebbeling

. Inadequate follow-up care for depression and its impact on antidepressant treatment duration among veterans with and without diabetes mellitus in the veterans health administration. Gen Hosp Psychiatry. 2006;28(6):465–474.

59.

Charbonneau

Rosen

Owen

, et al. Monitoring depression care: in search of an accurate quality indicator. Med Care. 2004;42(6):522–531.

60.

Leleu

Minvielle

. Relationship between longitudinal continuity of primary care and likelihood of death: analysis of national insurance data. PloS one. 2013;8(8):e71669.

61.

Maarsingh

Henry

van de Ven

, et al. Continuity of care in primary care and association with survival in older people: a 17-year prospective cohort study. Br J Gen Pract. 2016;66(649):e531–e539.

62.

Vasiliadis

H-M

Gontijo Guerra

Berbiche

, et al. The factors associated with 3-year mortality stratified by physical and mental multimorbidity and area of residence deprivation in primary care community-living older adults. J Aging Health. 2021;33(7-8):545–556.

63.

Guerra S

Berbiche

Vasiliadis

. Measuring multimorbidity in older adults: comparing different data sources. BMC Geriatr. 2019;19(1):166.

64.

Statistics Canada. Table 13-10-0096-16 Has a regular healthcare provider, by age group. https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310009616. Published 2021. Accessed 22 March, 2021.

65.

Tombaugh

McIntyre

. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc. 1992;40(9):922–935.

66.

Connors

Sachdev

, et al. Cognition and mortality in older people: the Sydney Memory and Ageing Study. Age Ageing. 2015;44(6):1049–1054.

67.

Institut National de Santé et des Services Sociaux. Accès équitable aux services de psychothérapie au québec. Québec, Québec: INESSS; 2017.

68.

Tannenbaum

. Inappropriate benzodiazepine use in elderly patients and its reduction. J Psychiatry Neurosci. 2015;40(3):E27–E28.

Minimally Adequate Treatment for Depression and Anxiety Associated With Mortality in Primary Care Older Adults

Abstract

Objective

Method

Results

Conclusion

Keywords

Introduction

Methods

Study Sample

Measures

Analyses

Results

Discussion

Footnotes

Acknowledgment

Authors’ Contribution

Data Availability

Declaration of Conflicting Interests

Funding

ORCID iDs

References